191 related articles for article (PubMed ID: 24947467)
1. Blood-brain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-glycoprotein substrates in cynomolgus monkeys.
Uchida Y; Wakayama K; Ohtsuki S; Chiba M; Ohe T; Ishii Y; Terasaki T
J Pharmacol Exp Ther; 2014 Sep; 350(3):578-88. PubMed ID: 24947467
[TBL] [Abstract][Full Text] [Related]
2. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
Uchida Y; Ohtsuki S; Kamiie J; Terasaki T
J Pharmacol Exp Ther; 2011 Nov; 339(2):579-88. PubMed ID: 21828264
[TBL] [Abstract][Full Text] [Related]
3. Pharmacoproteomics-based reconstruction of in vivo P-glycoprotein function at blood-brain barrier and brain distribution of substrate verapamil in pentylenetetrazole-kindled epilepsy, spontaneous epilepsy, and phenytoin treatment models.
Uchida Y; Ohtsuki S; Terasaki T
Drug Metab Dispos; 2014 Oct; 42(10):1719-26. PubMed ID: 25061162
[TBL] [Abstract][Full Text] [Related]
4. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats.
Sugimoto H; Hirabayashi H; Kimura Y; Furuta A; Amano N; Moriwaki T
Drug Metab Dispos; 2011 Jan; 39(1):8-14. PubMed ID: 20962062
[TBL] [Abstract][Full Text] [Related]
5. Quantitative investigation of the brain-to-cerebrospinal fluid unbound drug concentration ratio under steady-state conditions in rats using a pharmacokinetic model and scaling factors for active efflux transporters.
Kodaira H; Kusuhara H; Fuse E; Ushiki J; Sugiyama Y
Drug Metab Dispos; 2014 Jun; 42(6):983-9. PubMed ID: 24644297
[TBL] [Abstract][Full Text] [Related]
6. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier.
Hsiao P; Bui T; Ho RJ; Unadkat JD
Drug Metab Dispos; 2008 Mar; 36(3):481-4. PubMed ID: 18057117
[TBL] [Abstract][Full Text] [Related]
7. In vivo induction of P-glycoprotein expression at the mouse blood-brain barrier: an intracerebral microdialysis study.
Chan GN; Saldivia V; Yang Y; Pang H; de Lannoy I; Bendayan R
J Neurochem; 2013 Nov; 127(3):342-52. PubMed ID: 23777437
[TBL] [Abstract][Full Text] [Related]
8. Quantification of Transporter and Receptor Proteins in Dog Brain Capillaries and Choroid Plexus: Relevance for the Distribution in Brain and CSF of Selected BCRP and P-gp Substrates.
Braun C; Sakamoto A; Fuchs H; Ishiguro N; Suzuki S; Cui Y; Klinder K; Watanabe M; Terasaki T; Sauer A
Mol Pharm; 2017 Oct; 14(10):3436-3447. PubMed ID: 28880093
[TBL] [Abstract][Full Text] [Related]
9. Species difference in brain penetration of P-gp and BCRP substrates among monkey, dog and mouse.
Kido Y; Nanchi I; Fusamae Y; Matsuzaki T; Akazawa T; Sawada H; Iwasaki M; Nishida K; Tsuchiya E; Okuda T
Drug Metab Pharmacokinet; 2022 Feb; 42():100426. PubMed ID: 34974334
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier in humans.
Sugimoto H; Hirabayashi H; Amano N; Moriwaki T
Drug Metab Dispos; 2013 Apr; 41(4):683-8. PubMed ID: 23340958
[TBL] [Abstract][Full Text] [Related]
11. Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein.
Inoue T; Osada K; Tagawa M; Ogawa Y; Haga T; Sogame Y; Hashizume T; Watanabe T; Taguchi A; Katsumata T; Yabuki M; Yamaguchi N
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Oct; 39(1):156-62. PubMed ID: 22691713
[TBL] [Abstract][Full Text] [Related]
12. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport.
Syvänen S; Lindhe O; Palner M; Kornum BR; Rahman O; Långström B; Knudsen GM; Hammarlund-Udenaes M
Drug Metab Dispos; 2009 Mar; 37(3):635-43. PubMed ID: 19047468
[TBL] [Abstract][Full Text] [Related]
13. Use of cassette dosing approach to examine the effects of P-glycoprotein on the brain and cerebrospinal fluid concentrations in wild-type and P-glycoprotein knockout rats.
Liu X; Cheong J; Ding X; Deshmukh G
Drug Metab Dispos; 2014 Apr; 42(4):482-91. PubMed ID: 24398459
[TBL] [Abstract][Full Text] [Related]
14. Influence of time to achieve substrate distribution equilibrium between brain tissue and blood on quantitation of the blood-brain barrier P-glycoprotein effect.
Padowski JM; Pollack GM
Brain Res; 2011 Dec; 1426():1-17. PubMed ID: 22036081
[TBL] [Abstract][Full Text] [Related]
15. Investigation of utility of cerebrospinal fluid drug concentration as a surrogate for interstitial fluid concentration using microdialysis coupled with cisternal cerebrospinal fluid sampling in wild-type and Mdr1a(-/-) rats.
Nagaya Y; Nozaki Y; Takenaka O; Watari R; Kusano K; Yoshimura T; Kusuhara H
Drug Metab Pharmacokinet; 2016 Feb; 31(1):57-66. PubMed ID: 26830080
[TBL] [Abstract][Full Text] [Related]
16. Successful Prediction of Human Steady-State Unbound Brain-to-Plasma Concentration Ratio of P-gp Substrates Using the Proteomics-Informed Relative Expression Factor Approach.
Storelli F; Anoshchenko O; Unadkat JD
Clin Pharmacol Ther; 2021 Aug; 110(2):432-442. PubMed ID: 33675056
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood-brain barrier in vivo.
Bundgaard C; Eneberg E; Sánchez C
Neuropharmacology; 2016 Apr; 103():104-11. PubMed ID: 26700248
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid.
Kaddoumi A; Choi SU; Kinman L; Whittington D; Tsai CC; Ho RJ; Anderson BD; Unadkat JD
Drug Metab Dispos; 2007 Sep; 35(9):1459-62. PubMed ID: 17591677
[TBL] [Abstract][Full Text] [Related]
19. Impact of In Vitro Passive Permeability in a P-gp-transfected LLC-PK1 Model on the Prediction of the Rat and Human Unbound Brain-to-Plasma Concentration Ratio.
Nicolaï J; Chapy H; Gillent E; Saunders K; Ungell AL; Nicolas JM; Chanteux H
Pharm Res; 2020 Aug; 37(9):175. PubMed ID: 32856111
[TBL] [Abstract][Full Text] [Related]
20. Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid concentrations in rhesus monkeys.
Tang C; Kuo Y; Pudvah NT; Ellis JD; Michener MS; Egbertson M; Graham SL; Cook JJ; Hochman JH; Prueksaritanont T
Biochem Pharmacol; 2009 Sep; 78(6):642-7. PubMed ID: 19481060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
